Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer
For nearly three decades, chimeric antigen receptors (CARs) have captivated the interest of researchers seeking to find novel immunotherapies to treat cancer. CARs were first designed to work with T cells, and the first CAR T cell therapy was approved to treat B cell lymphoma in 2017. Recent advance...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/7/1493 |
| _version_ | 1827619162119208960 |
|---|---|
| author | Carlos Moreno Christopher Haynie Abigail Cheever K. Scott Weber |
| author_facet | Carlos Moreno Christopher Haynie Abigail Cheever K. Scott Weber |
| author_sort | Carlos Moreno |
| collection | DOAJ |
| description | For nearly three decades, chimeric antigen receptors (CARs) have captivated the interest of researchers seeking to find novel immunotherapies to treat cancer. CARs were first designed to work with T cells, and the first CAR T cell therapy was approved to treat B cell lymphoma in 2017. Recent advancements in CAR technology have led to the development of modified CARs, including multi-specific CARs and logic gated CARs. Other immune cell types, including natural killer (NK) cells and macrophages, have also been engineered to express CARs to treat cancer. Additionally, CAR technology has been adapted in novel approaches to treating autoimmune disease and other conditions and diseases. In this article, we review these recent advancements in alternative CAR therapies and design, as well as their mechanisms of action, challenges in application, and potential future directions. |
| first_indexed | 2024-03-09T10:22:22Z |
| format | Article |
| id | doaj.art-8a5304bcbf974f0683b7ae73c7ba07d3 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T10:22:22Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-8a5304bcbf974f0683b7ae73c7ba07d32023-12-01T21:55:03ZengMDPI AGBiomedicines2227-90592022-06-01107149310.3390/biomedicines10071493Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat CancerCarlos Moreno0Christopher Haynie1Abigail Cheever2K. Scott Weber3Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USADepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USADepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USADepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USAFor nearly three decades, chimeric antigen receptors (CARs) have captivated the interest of researchers seeking to find novel immunotherapies to treat cancer. CARs were first designed to work with T cells, and the first CAR T cell therapy was approved to treat B cell lymphoma in 2017. Recent advancements in CAR technology have led to the development of modified CARs, including multi-specific CARs and logic gated CARs. Other immune cell types, including natural killer (NK) cells and macrophages, have also been engineered to express CARs to treat cancer. Additionally, CAR technology has been adapted in novel approaches to treating autoimmune disease and other conditions and diseases. In this article, we review these recent advancements in alternative CAR therapies and design, as well as their mechanisms of action, challenges in application, and potential future directions.https://www.mdpi.com/2227-9059/10/7/1493T cellchimeric antigen receptorCARNK cellmacrophageautoimmune |
| spellingShingle | Carlos Moreno Christopher Haynie Abigail Cheever K. Scott Weber Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer Biomedicines T cell chimeric antigen receptor CAR NK cell macrophage autoimmune |
| title | Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer |
| title_full | Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer |
| title_fullStr | Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer |
| title_full_unstemmed | Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer |
| title_short | Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer |
| title_sort | alternative car therapies recent approaches in engineering chimeric antigen receptor immune cells to combat cancer |
| topic | T cell chimeric antigen receptor CAR NK cell macrophage autoimmune |
| url | https://www.mdpi.com/2227-9059/10/7/1493 |
| work_keys_str_mv | AT carlosmoreno alternativecartherapiesrecentapproachesinengineeringchimericantigenreceptorimmunecellstocombatcancer AT christopherhaynie alternativecartherapiesrecentapproachesinengineeringchimericantigenreceptorimmunecellstocombatcancer AT abigailcheever alternativecartherapiesrecentapproachesinengineeringchimericantigenreceptorimmunecellstocombatcancer AT kscottweber alternativecartherapiesrecentapproachesinengineeringchimericantigenreceptorimmunecellstocombatcancer |